Updated:
Aura Biosciences
Aura Biosciences is developing virus-like drug conjugate (VDC) therapies that mimic the natural targeting properties of oncoviruses to deliver a...
Aura Biosciences
Aura Biosciences is developing virus-like drug conjugate (VDC) therapies that mimic the natural targeting properties of oncoviruses to deliver a photoactivated payload specifically to cancer cells. The company was founded by Dr. Elisabet de los Pinos, who leads the firm as CEO. The technology originated from research seeking to use viral capsids — the protein shells of viruses — as a targeted delivery mechanism for cytotoxic drugs. Aura's approach is designed to preserve healthy tissue by confining treatment to malignant cells, a significant departure from the diffuse toxicity common in traditional chemotherapy and radiotherapy. The company's pipeline is anchored by belzupacap sarotalocan (AU-011), a VDC conjugate targeting malignant cells in the eye. The drug is administered via intravitreal injection, then activated by a near-infrared laser to produce localized tumor necrosis. Aura is pursuing two distinct applications: a vision-preserving treatment for early-stage choroidal melanoma, now in a global Phase 3 trial (per the firm's official communications), and a second program investigating the same candidate for choroidal metastasis. The firm has also secured Fast-Track and Orphan Drug designations from the FDA for its lead asset. Beyond ocular oncology, Aura is exploring the platform's potential in non-muscle invasive bladder cancer through a separate preclinical candidate. Aura Biosciences is headquartered in Boston, Massachusetts, with research operations in Cambridge. As a clinical-stage company, the firm's resources are concentrated on advancing its Phase 3 program and supporting clinical trial sites across North America and Europe. The company went public via a NASDAQ listing in 2021 through a standard IPO process. Recent operational activity includes ongoing patient enrollment for the pivotal Phase 3 CoMpass trial evaluating belzupacap sarotalocan for early-stage choroidal melanoma. Aura's structural differentiator lies in its two-part therapeutic approach: a targeted biological delivery mechanism paired with a localized, physician-controlled activation step. This model transforms the treatment of ocular tumors from invasive surgery or full-eye radiotherapy into an outpatient ophthalmic injection followed by a laser procedure, preserving the structure of the eye while destroying the tumor. The company's platform is built on a biology-first principle of viral mimicry, a technique more commonly explored in gene therapy than in targeted oncology, giving it a distinct scientific profile among cancer drug developers.
General information
Firm type
Unclassified
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What is the mechanism of action behind Aura's VDC platform?
Aura's virus-like drug conjugates (VDCs) are built from engineered human papillomavirus (HPV) capsids that bind selectively to modified heparan sulfate proteoglycans commonly found on the surface of cancer cells. After local administration, the conjugated infrared-activated cytotoxic agent is photoactivated with a near-infrared laser, causing rapid and selective necrosis of the bound tumor cells while leaving surrounding healthy tissue intact.
Why is Aura focusing on ocular cancers for its lead indication?
Choroidal melanoma is a rare, underserved cancer with no approved drug therapy; current treatments involve either radiation plaques that blind the eye or complete surgical removal. The eye is also an accessible, self-contained organ where a localized injection and laser treatment can be delivered precisely, making it an ideal proving ground for the targeted VDC mechanism before expanding into other solid tumor types.
What is the status of belzupacap sarotalocan's regulatory review?
Belzupacap sarotalocan is currently in a global Phase 3 registrational trial called CoMpass, which completed full enrollment in mid-2024. The FDA has granted the candidate both Fast-Track and Orphan Drug designations for the treatment of primary choroidal melanoma, which generally provide for more frequent regulatory dialogue and potential eligibility for priority review.
Does Aura Biosciences have collaborations or partnerships with larger pharmaceutical companies?
Aura has not disclosed a global commercial partnership for its lead program, retaining full development and commercialization rights for ocular oncology. The company has funded its pipeline primarily through public equity markets following its 2021 NASDAQ listing, supplemented by prior venture investment rounds. No joint venture or co-development agreement with a major pharmaceutical partner has been announced public record.
What is the company's financial position, and how long is its cash runway?
Aura Biosciences reports a cash and marketable securities balance intended to fund operations into the second half of 2026, according to its most recent quarterly filings. As a pre-revenue biotechnology company, its capital allocation focuses almost exclusively on completing the Phase 3 CoMpass trial and preparing commercial manufacturing capabilities.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: